Researchers have found that endocrine-targeted therapies and an assessment of biomarkers in sex hormone and insulin signaling pathways may be useful in the prevention and treatment of endometrial cancer recurrence.

"These findings are very encouraging," said researcher Gloria Huang, Associate Professor at Yale University in the US.

For the study, published in the journal Cancer Epidemiology Biomarkers and Prevention, the team analysed blood serum and endometrial tumour samples from several hundred women who participated in the study.

The focus was on women with the most common type of endometrial cancer, endometrioid adenocarcinoma, who were at risk for recurrence due to higher stage at presentation (Stages II to IV).

Circulating estradiol hormone and positivity for phosphorylated IGF1R/IR (pIGF1R/pIR), the activated form of cellular receptors for insulin-like growth factors and insulin were associated with increased recurrence risk.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT).